PatientsVille.com Logo

ACUTE KIDNEY INJURY and Oxycodone

PatientsVille

ACUTE KIDNEY INJURY Symptoms and Causes

You have two kidneys, each about the size of your fist. They are near the middle of your back, just below the rib cage. Inside each kidney there are about a million tiny structures called nephrons. They filter your blood. They remove wastes and extra water, which become urine. The urine flows through tubes called ureters. It goes to your bladder, which stores the urine until you go to the bathroom.

Most kidney diseases attack the nephrons. This damage may leave kidneys unable to remove wastes. Causes can include genetic problems, injuries, or medicines. You have a higher risk of kidney disease if you have diabetes, high blood pressure, or a close family member with kidney disease. Chronic kidney disease damages the nephrons slowly over several years. Other kidney problems include

  • Cancer
  • Cysts
  • Stones
  • Infections

Your doctor can do blood and urine tests to check if you have kidney disease. If your kidneys fail, you will need dialysis or a kidney transplant.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for ACUTE KIDNEY INJURY

ACUTE KIDNEY INJURY treatment research studies

Oxycodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Oxycodone Side Effects

Completed Suicide (541)
Respiratory Arrest (500)
Cardiac Arrest (472)
Toxicity To Various Agents (364)
Cardio-respiratory Arrest (309)
Nausea (300)
Poisoning (264)
Overdose (263)
Exposure Via Ingestion (248)
Vomiting (245)
Death (235)
Pain (219)
Somnolence (218)
Substance Abuse (199)
Confusional State (188)
Constipation (188)
Delirium (178)
Headache (164)
Dizziness (162)
Accidental Overdose (148)
Dyspnoea (110)
Anxiety (94)
Diarrhoea (87)
Fall (85)
Loss Of Consciousness (85)
Road Traffic Accident (85)
Depressed Level Of Consciousness (76)
Asthenia (74)
Hyperhidrosis (72)
Lethargy (72)
Abdominal Pain (71)
Coma (71)
Malaise (70)
Product Quality Issue (70)
Agitation (69)
Pruritus (68)
Depression (64)
Mental Status Changes (64)
Fatigue (63)
Insomnia (61)
Impaired Driving Ability (60)
Feeling Abnormal (59)
Unresponsive To Stimuli (57)
Product Substitution Issue (56)
Rash (55)
Pneumonia (54)
Inadequate Analgesia (54)
Back Pain (54)
Malignant Neoplasm Progression (50)
Dehydration (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am searching for how oxycodone affects ascites.

<strong></strong><span style='text-decoration: underline;'>Have severe back and knee pain. One of the shots in my back worked and I got off oxycodone for a couple of weeks by taking

Depression of Pituitary function, requiring hormone replacement

I been taking oxycodone for months now and wanted to know about withdrawl

I was prescribed this medication after months of being on just oxycodone. I had major side effects from the naloxone. It made me very depressed and also gave me extreme migrane headaches. Also made my legs feel tracing pain and prevented me from slee

It seems i have to take to function on a daily

Itching

What's on your miRnd...im too tired on this new oxycontin, pain relie is not enough

<span style='color: #808080;'><b>Describe Your Injection site swelling from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: I am 46, Female on discharge from hospital 12.6.10 10pm after treatment for acute diverticuli

<span style='visibility: visible;'><span style='visibility: visible;'>After battling with acute insomnia for about 3 months, my GP prescribed Trimipramine 25mg. This still didn't get me much sleep, so he prescribed Purata 30mg. Better, bu

5th Week of Champix, so not smoked now for 3 weeks. Have experienced really bad headaches, mainly in the eyes, like acute sinisitus, will have to go to doctors to see if being caused by champix. Hope I do not have to come off them

Acute lower back pain causing lack of mobility?

Acute psychosis

Acutecontinuous incontinence

After 10 days of taking Aclasta serum 5mg i had all the side effects and after 10 days i still have chills and bone pain, what should i do? By the way im having a blood test tomorrow to know about the kidney,liver and glucose. so what should i do??

After a urinalisis the doctor told me there were no white blood cells, only red blood cells in urine. drew blood and had cat scan and revealed a 7mm kidney stone. but i'm worried about having no white blood cell count in my urine

After prolonged use my mother had kidney failier.DR did not want to point a finger but 1 took me aside and said Please do something I cannot.Do not use Metamucil orginal texure for a prolonged period.she used it for a long time and now theres no moth

After the kidney transplant my daughter's glucouse level was very high due to tacrolimus At the moment she takes insulin I want to know that the damage tacrolimus was done for the beta cells are permanant? little by little the units she takes reducin

ACUTE KIDNEY INJURY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Abuse Liability of Controlled-Release Oxycodone Formulations
Condition: Substance-Related Disorders
Interventions: Drug: Apo-Oxycodone CR®;   Drug: OxyNEO®;   Drug: OxyContin®;   Drug: Placebo
Outcome Measures: Change from Baseline on Visual Analogue Scale for "Drug Liking" Over 8 Hours After Drug Administration;   Change from Baseline on Visual Analogue Scale for "Drug High" Over 8 Hours After Drug Administration;   Pupil Diameter;   Cmax;   Profile of Mood States (POMS);   Psychomotor Performance;   Visual Analogue Scale for "Any Drug Effects";   Visual Analogue Scale for "Good Effects";   Visual Analogue Scale for "Bad Effects";   Visual Analogue Scale for "Feel Sick";   Visual Analogue Scale for "Nausea";   Visual Analogue Scale for "Sleepy";   Visual Analogue Scale for "Dizzy";   Sedation;   Euphoria;   Dysphoric Changes;   Psychotomimetic Changes;   Somatic Disturbances;   Sensory Disturbances;   Tmax
2 Recruiting Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery
Condition: Arthroplasty, Replacement, Hip
Interventions: Drug: Standard Care morphine hydrochloride;   Drug: Oxycodone
Outcome Measures: Composite score of complications;   Number of opioid boluses in the post-intervention surveillance room;   Time to obtain a VAS score < 30/100 (from the first administration; minutes);   Length of stay in the post-intervention surveillance room (minutes);   Total dose of opioids during the first 24 hours (mg);   Total number of opioid requestions (patient controlled analgesia = PCA);   Total number of opioid requestions accepted / refused (PCA);   Ramsay score;   Presence / absence of an overdose of morphine/Oxycodone (Ramsay score > 4);   Presence / absence of an overdose of morphine/Oxycodone (Ramsay score> 4);   Presence/absence of complications;   Patient satisfaction, VAS scale;   Pain while at rest at while moving (Visual Analog Scale);   DN4 score;   Length of hospital stay (hours)
3 Recruiting Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain
Condition: Postcraniotomy Pain
Interventions: Drug: Oxycodone;   Drug: Codeine
Outcome Measures: To determine the difference in the mean pain VAS scores in the Oxycodone and codeine groups at 24hr.;   To look at the incidence of adverse events in the Oxycodone and codeine groups.
4 Recruiting A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Condition: Cancer
Intervention: Drug: Oxycodone and naloxone
Outcome Measures: Assess reduction of pain intensity;   Efficacy parameters including long term safety and efficacy
5 Not yet recruiting Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
Condition: Pediatric Surgical Patient
Intervention: Drug: oral Oxycodone
Outcome Measure: Oxycodone, oxymorphone, noroxymorphone and norOxycodone serum levels
6 Recruiting Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Condition: Pain
Intervention: Drug: Oxycodone HCl controlled-release tablets
Outcome Measures: The number of participants with adverse events as a measure of safety.;   To characterize the efficacy and provide additional pharmacokinetics (PK) data of Oxycodone hydrochloride controlled-release tablets
7 Unknown  Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: etoricoxib;   Drug: Oxycodone
Outcome Measures: Proportion of patients achieving a > 30% reduction in avg daily pain intensity at treatment week 4 (Visit 4).;   Proportion of patients achieving a > 50% reduction in avg daily pain intensity at treatment week 5 (visit 4).
8 Recruiting Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
Condition: Pain
Intervention: Drug: Oxycodone
Outcome Measures: Cmax of Oxycodone Oral Solution.;   Safety of Oxycodone Oral Solution in Pediatric Patients
9 Not yet recruiting Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Oxycodone
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Concentration at time 24 hours (C24);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2)
10 Unknown  A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
Condition: Post Tonsillectomy Pain
Interventions: Drug: 0,1 mg/kg of Oxycodone;   Drug: Morphine 0,1 mg/kg;   Drug: Dexamethasone 0,5 mg/kg;   Drug: NaCl 0,9%
Outcome Measures: The difference of needed rescue pain medication post operatively;   differences in adverse effects
11 Recruiting An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
Condition: Spinal Disorders Related Pain
Intervention: Drug: Oxycodone/Naloxone
Outcome Measures: 24hr pain intensity score (Numeric rating score: 0 -10);   EuroQol-5 Dimension(EQ-5D);   Overall satisfaction of Physicians and subjects
12 Recruiting Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur
Condition: Pain, Postoperative
Interventions: Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Mobilization measured daily using Cumulated Ambulation Score.;   Pain intensity measured daily on a verbal rating scale;   Adverse effects;   Opioid consumption.;   Length of stay in Hospital
13 Not yet recruiting A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Conditions: Postoperative Pain;   Postoperative Nausea and Vomiting
Interventions: Drug: Targinact;   Drug: Oxycodone;   Procedure: Laparoscopic segmental colectomy
Outcome Measures: Prevalence of postoperative gut dysfunction;   Pain control;   Oral analgesia use;   Pain scores
14 Recruiting Targin Cancer Pain
Conditions: Cancer;   Pain
Interventions: Drug: Oxycodone/Naloxone;   Drug: Oxycodone
Outcome Measures: BFI-Bowel Function Index;   BPI-Brief Pain Index
15 Not yet recruiting A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: GL2907;   Drug: Oxycontine CR 10mg
Outcome Measures: Cmax,ss;   AUCτ;   Tmax;   t1/2;   Vz/f;   CL/F;   Cmin,ss;   Cave,ss;   degree og fluctuation;   swing;   R
16 Recruiting Targin for Non-cancer Pain
Condition: Non Cancer Pain
Intervention: Drug: Oxycodone/naloxone prolonged release tablets
Outcome Measures: Bowel function index(BFI) 12 Weeks;   Modified BPI-SF-Average Pain over the last 24 hours
17 Recruiting RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Conditions: Cancer;   Cancer Pain
Interventions: Drug: Morphine;   Drug: Fentanyl;   Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Proportion of Non-Responder (NR) patients;   Proportion of full-responder
18 Recruiting Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Conditions: Opioid Abuse;   Opioid Dependence
Interventions: Drug: MN-166 (formerly AV411);   Drug: placebo
Outcome Measures: pain intensity;   positive subjective effects to Oxycodone
19 Recruiting Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Condition: Opioid Abuse
Intervention: Drug: pioglitazone
Outcome Measures: Subjective ratings of drug, mood, and physiological effects;   Analgesic responses using the cold pressor test
20 Recruiting Abuse Potential Study of PF-00345439
Condition: Opioid Users
Interventions: Drug: Capsule;   Drug: PF-00345439;   Drug: Oxycodone
Outcome Measures: Drug Liking: Peak Effect (Emax);   High: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours;   High: Area Under Effect Curve (AUE) From 0-2 Hours;   Take Drug Again Effect at 24 Hours;   Overall Drug Liking;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour;   Chewing Duration;   Taste: Subjective Experience from Chewing;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-2 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-3 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-12 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-3 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours;   High: Area Under Effect Curve (AUE) From 0-1 Hour;   High: Area Under Effect Curve (AUE) From 0-3 Hours;   High: Area Under Effect Curve (AUE) From 0-12 Hours;   Good Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-1 Hour;   Feeling Sick: Area Under Effect Curve (AUE) From 0-2 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-3 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-12 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-1 Hour;   Nausea: Area Under Effect Curve (AUE) From 0-2 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-3 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-12 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour;   Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-3 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-12 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-3 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Effects: Peak Effect (Emax);   Nausea: Peak Effect (Emax);   Feel Sick: Peak Effect (Emax);   Sleepy: Peak Effect (Emax);   Dizzy: Peak Effect (Emax);   Pupillometry: Peak Effect (Emax);   Good Drug Effects: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour;   Drug Liking: Area Under Effect Curve (AUE) From 0-3 Hours;   Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours;   Drug Liking: Time to Maximum (Peak) Effect (TEmax);   High: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Good Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Feel Sick: Time to Maximum (Peak) Effect (TEmax);   Nausea: Time to Maximum (Peak) Effect (TEmax);   Sleepy: Time to Maximum (Peak) Effect (TEmax);   Dizzy: Time to Maximum (Peak) Effect (TEmax);   Pupillometry: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Peak Effect (Emax);   Texture: Subjective Experience from Chewing;   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Area under the curve (AUC);   Systemic Clearance (CL);   volume of distribution (Vd);   Half-Life (t1/2)